DSM-Firmenich stock: Citi raises target to EUR 111 from EUR 106

Published on 10/20/2026 at 15:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Buyback reached EUR 540 million on October 1, 2026. DSM-Firmenich stock costs EUR 108.53 on October 20, 2026, plus 0.58 percent versus Xetra close.

Target and operating figures

Citi raised its DSM-Firmenich target from EUR 106.00 to EUR 111.00.
Second-quarter 2026 revenue was EUR 2.39 billion, with EBITDA of EUR 466.00 million.
DSM-Firmenich stock costs EUR 108.53 at Lang & Schwarz on October 20, 2026 at 3:08 p.m. CEST, 0.58 percent above the Xetra close of October 19, 2026, and 1.20 percent below the 52-week high.
The planned share cancellation is due by the end of the first quarter of 2027.

Makroaufnahme goldener Aromastoff-Öltropfen mit Vitaminkristallen auf Glas — dsm-firmenich AG (ISIN CH1216478797) stellt Aromastoffe her, als goldene Öltropfen in extremer Makroaufnahme gezeigt, Illustration mit AI erstellt.

DSM-Firmenich (ISIN CH1216478797) has a fresh analyst target of EUR 111.00 after Citi raised it from EUR 106.00, according to Markets Insider on October 2, 2026. The target stands 2.26 percent above the EUR 108.53 price. DSM-Firmenich was trading at EUR 108.53 at Lang & Schwarz on October 20, 2026 at 3:08 p.m. CEST, plus 0.58 percent versus the Xetra close of October 19, 2026 at EUR 107.90.

Second-quarter revenue reached EUR 2.39 billion

For the second quarter of 2026, revenue was EUR 2.39 billion, down 26.20 percent, while EBITDA reached EUR 466.00 million and the EBITDA margin was 19.50 percent, according to Ideal Investisseur. The figures give the target price a fundamental reference beyond the recent share performance.

Stock stays 1.20 percent below its high

The EUR 108.53 quotation at Lang & Schwarz on October 20, 2026 at 3:08 p.m. CEST sits between the 52-week range of EUR 55.22 to EUR 109.85 as of the same market snapshot. That leaves the stock 1.20 percent below its 52-week high and 96.53 percent above its 52-week low. Trading volume stood at 122,604 shares at the same timestamp.

Buyback cancellation due in 2027

The completed repurchase program totaled EUR 540 million and covered 7,169,147 shares, according to FinanzNachrichten on October 1, 2026. The company intends to cancel 6,488,446 shares by the end of the first quarter of 2027, reducing issued shares from 253,626,947 to 247,138,501.

Comparison with peers

DSM-Firmenich: up 0.58 percent versus the Xetra close, market capitalization EUR 26.5 billion as of October 20, 2026. BASF (Xetra, EUR): down 0.55 percent, P/E 7.88, market capitalization EUR 45.2 billion as of October 20, 2026. Symrise (Xetra, EUR): down 0.35 percent, P/E 37.67, market capitalization EUR 13.8 billion as of October 20, 2026.

Analyst target remains the key comparison

Citi's EUR 111.00 target is 2.26 percent above the Lang & Schwarz price, while the stock remains 1.20 percent below its 52-week high. The combination places the analyst target close to the recent trading peak without making it a forecast.

The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.